By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical trial approvals from the National Medical Products Administration (NMPA) for its HRS-1167, SHR-4658, and HRS9531. These approvals mark significant progress in the development of novel therapies for diverse medical conditions.
HRS-1167: PARP1 Inhibitor for Prostate Cancer
HRS-1167 is an oral PARP1 inhibitor designed to enter a Phase Ib/II study in combination with abiraterone and prednisone (AA-P) for metastatic prostate cancer. This next-generation inhibitor demonstrates higher selectivity and affinity for PARP1, positioning it for potential use as both a monotherapy and a combination therapy. Its development aims to expand treatment options for patients, including those previously ineligible for PARP inhibitors.
SHR-4658: First-in-Class Heart Failure Treatment
SHR-4658, a Category 1 drug with undisclosed targets, represents a novel approach to heart failure treatment. As the first of its kind globally, this drug highlights Hengrui’s commitment to addressing unmet medical needs in cardiology.
HRS9531: Dual Agonist for Obesity and Sleep Apnea
HRS9531, a GIP/GLP-1 receptor dual agonist, is advancing into clinical trials for obstructive sleep apnea combined with obesity. This Phase III study builds on its existing trials for weight loss and blood sugar management, further expanding the therapeutic potential of this dual-action mechanism.-Fineline Info & Tech